Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Brice Andring

Vascular & Interventional Radiology Fort Worth, TX Medical Doctor

NPI 1720354350 CMS profile 3842051

815 Pennsylvania Ave, Fort Worth, TX 76104

Open in the dashboard

General payments

$62,952

219 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Brice Andring of Fort Worth, TX is reported in the CMS Open Payments database as having received $62,952 across 219 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 91st percentile of Vascular & Interventional Radiology profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $24,494 39
2024 General $22,978 50
2023 General $9,061 44
2022 General $3,847 39
2021 General $1,117 20
2020 General $149 7
2019 General $1,305 20

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Brice Andring
  • Vascular & Interventional Radiology median
  • Middle half of Vascular & Interventional Radiology
  • National median

In program year 2025, general payments to Brice Andring were reported at $24,494. Among 3,393 Vascular & Interventional Radiology profiles paid that year, the median was $534 and the middle half received between $166 and $2,075.

Show as a table
Year Brice Andring Vascular & Interventional Radiology median Middle half National median
2019 $1,305 $422 $125–$1,555 $163
2020 $149 $200 $68–$652 $114
2021 $1,117 $280 $99–$866 $132
2022 $3,847 $433 $137–$1,497 $149
2023 $9,061 $506 $152–$2,019 $160
2024 $22,978 $556 $175–$1,930 $164
2025 $24,494 $534 $166–$2,075 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Sirtex Medical Inc $57,502 59 payments
  2. Balt USA, LLC $1,022 38 payments
  3. Philips Electronics North America Corporation $813 4 payments
  4. Boston Scientific Corporation $730 38 payments
  5. Inari Medical, Inc. $685 17 payments
  6. Stryker Corporation $495 13 payments
  7. AngioDynamics, Inc. $388 6 payments
  8. Medtronic, Inc. $375 11 payments
  9. Medtronic Vascular, Inc. $191 9 payments
  10. Abbott Laboratories $182 3 payments
  11. Other $568 21 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program $53,100 15 payments
  2. Food and Beverage $6,454 190 payments
  3. Travel and Lodging $3,087 13 payments
  4. Education $310 1 payment
Products named General payments · program years 2019–2025
  1. SIR-Spheres Microspheres $50,402 57 payments
  2. LAVA LES (Liquid Embolic System) $7,100 2 payments
  3. Prestige Coil System $1,000 37 payments
  4. CT THROMBECTOMY SYSTEM KIT $749 20 payments
  5. FLOWTRIEVER CATHETER, S $749 20 payments
  6. IGT D Peripheral $708 3 payments
  7. VenaCure 1470 Pro $322 2 payments
  8. Concerto $156 7 payments
  9. Perclose ProGlide suture mediated closure system $145 1 payment
  10. INTELLIS ADAPTIVESTIM $144 1 payment
  11. Other $2,037 81 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 4 drugs

Part D claims

75

Median for Interventional Radiology: 38

Drug cost

$780

Median for Interventional Radiology: $333

Branded share of claims

0%

Median for Interventional Radiology: 53%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Sucralfate Generic 19 $426
Metoclopramide Hcl Generic 18 $132
Methylprednisolone Generic 20 $121
Omeprazole Generic 18 $102

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 554 Part D prescribers listed as Interventional Radiology; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 162 billing codes

Paid by Medicare

$106,961

Of which drugs: $256

Medicare patients

536

Average age 72

Services billed

2,815

283 women, 253 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Arthritis 54%
Diabetes 44%
Chronic kidney disease 42%
Ischemic heart disease 36%
Cancer 30%
COPD 29%
Heart failure 27%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Records

219 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Vascular & Interventional Radiology in Texas

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record